Jnc Corporation

Tokyo Medical and Dental University

Kyoto University

Tokyo Institute of Technology

Kinopharma, Inc.

Other

Kagoshima University

Gifu University

Masatoshi Hagiwara

Riken Corporation

Hagiwara, Masatoshi

Takeshi Fukuhara

Takamitsu Hosoya

Masaaki Suzuki

Satoshi Inouye

Suguru Yoshida

Yuiko Sahara

Isao Kii

Yuiko Miura

Hiroshi Onogi

Takashi Kurihara

Hisashi Doi

Rie Iimori

Yuto Sumida

Takeshi Matsushita

Hiroko Koyama

Kohei Oka

Shigeomi Shimizu

Akiko Kobayashi

Michiko Murohashi

Hirotaka Onoe

Toshiyuki Hiramatsu

Masayasu Toyomoto

Yasuyoshi Watanabe

Kayo Takahashi

Provided is a composition for activating neurogenesis, use of the composition, and a method for preventing, improving, inhibiting the development of, and/or treating a disease or the like of the central nervous system and or the peripheral nervous system using the composition. A composition for activating neurogenesis contains, as an active ingredient, a compound having an ability to inhibit phosphorylation activity of a protein kinase or a prodrug thereof, or a pharmaceutically acceptable salt thereof, and a composition for preventing, improving, inhibiting the development of, and/or treating a disease of the central nervous system and/or the peripheral nervous system, or for improving, inhibiting the development of, and/or treating a functional disorder of the central nervous system and/or the peripheral nervous system, the composition containing, as an active ingredient, a compound having an ability to inhibit phosphorylation activity of a protein kinase or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

Composition for activating neurogenesis

It has been found that efficient screening for a compound having anticancer activity can be achieved by selecting a compound having activity to induce alternative autophagy using, as an index, formation of fluorescent bright spots due to aggregation of a lysosomal protein to which a fluorescent protein is attached in cells expressing the lysosomal protein. In addition, it has been found that a benzothiophene compound represented by the following general formula (1) has alternative autophagy-inducing activity and anticancer activity: 

Benzothiophene compound, alternative autophagy-inducing agent and anticancer agent including the compound as active ingredient, and method for screening for compound having anticancer activity

The present invention provides a compound and a pharmaceutical composition for neuropsychological disorders or malignant tumors, the use of the compound and the pharmaceutical composition, or a method for preventing, improving, inhibiting the development of, and/or treating neuropsychological disorders or malignant tumors with the use of the compound and the pharmaceutical composition. One or more embodiments disclose a compound expressed by the following general formula (I) or (II) or a pharmaceutically acceptable salt of the compound: 

Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor

A compound and a pharmaceutical composition for disease associated with an abnormal splice variant, use of the compound and the pharmaceutical composition, or a screening method of the compound and the pharmaceutical composition are provided. One or more embodiments disclose a compound expressed by the following formula (I) or (I') or prodrugs or pharmaceutically acceptable salts thereof. Another one or more embodiments disclose a screening method using a DNA construct that is fused, arranged, or constructed so as to express different reporter genes for a wild-type splice variant and an abnormal splice variant that contributes to the development or progression of disease; 

Method for screening substance capable of inhibiting abnormal splicing causative of onset or progress of disease

Provided is a pain-related compound, a pain-related pharmaceutical composition, and use of the same. Provided in one or more embodiments is a compound represented by Formula (I), a prodrug of the same, or a pharmaceutically permissible salt of any of the same. 

Pain-related compound and medical composition

There has been a need for coelenterazine analogs that exhibit luminescence properties different from those of known coelenterazine analogs. The present invention provides the compound represented by general formula (1). 

Substituted imidazo[1,2-A]pyrazines for measuring a transcription activity

The invention aims in establishing a method for modifying biomolecules using a reaction that efficiently modifies biomolecules and is widely applicable. The invention thus provides a cyclic compound containing two triazole rings formed by adding and ligating an azide compound possessing an azido group to each of the two carbon-carbon triple bond sites of an eight-membered cyclic skeleton of a cyclic diyne compound by a double click reaction; a method for producing a cyclic compound using a double click reaction; and a method for modifying biomolecules.

Cyclic compound, method for producing cyclic compound, and method for modifying biological molecule

Described include (1) a substituted pyrazine compound of general formula (VIII): and (2) a process for producing the substituted pyrazine compound of general formula (VIII), where Ris hydrogen, a halogen, a substituted or unsubstituted hydrocarbon group, or a substituted or unsubstituted heterocyclic group, and Ris a protecting group. The process comprises (1) the step of reacting 2-amino-3,5-dibromo-6-chloropyrazine with RMgX and ZnClin the presence of a palladium catalyst to produce a compound of general formula (V); (2) the step of reacting the compound of general formula (V) with a compound of general formula (VI) to produce a compound of general formula (VII); and (3) the step of reacting the compound of formula (VII) with tributyl(vinyl)tin in the presence or a palladium catalyst to given the compound of general formula (VIII).

Substituted pyrazines and a process for producing the same

Coelenterazine analogs and manufacturing method thereof

Coelenterazine analogs with different luminescence properties from conventional ones and coelenteramide analogs with different fluorescence properties from conventional ones have been desired. The invention provides coelenterazine analogs modified at the 8-position of coelenterazine and coelenteramide analogs modified at the 2- or 3-position of coelenteramide.

Coelenterazine analogues and coelenteramide analogues

A simple process for producing v-coelenterazine compounds has been desired. Described is a process for producing a v-coelenterazine compound represented by general formula (II) comprising (1) the step of reacting a compound of general formula (VIII) with a methyltriphenylphosphonium salt in the presence of a base to give a compound represented by general formula (IX), (2) the step of performing a ring-closing metathesis reaction on any one selected from the group consisting of the compound represented by general formula (IX) and a compound of general formula (X) which is the compound of general formula (IX) wherein the amino is protected with R, and then deprotecting Rand, if any, Rto give a v-coelenteramine compound represented by general formula (XIV), and (3) the step of reacting the compound of general formula (XIV) with a compound represented by general formula (XV) to give the compound of general formula (II).

Process for producing substituted benzo[F]imidazo[1,2-A]quinoxalin-3(11H)-ones

Growing community of inventors

Tokyo, Japan

Takamitsu Hosoya